David Kao
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 34 | 2024 | 2228 | 5.190 |
Why?
| | Machine Learning | 7 | 2024 | 487 | 2.320 |
Why?
| | Stroke Volume | 17 | 2025 | 619 | 2.000 |
Why?
| | Methadone | 5 | 2023 | 98 | 1.570 |
Why?
| | Adrenergic beta-Antagonists | 10 | 2025 | 323 | 1.540 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 77 | 1.510 |
Why?
| | Buprenorphine | 3 | 2023 | 167 | 1.400 |
Why?
| | Cardiomyopathies | 5 | 2022 | 350 | 1.370 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 218 | 1.280 |
Why?
| | United States Food and Drug Administration | 5 | 2024 | 207 | 1.260 |
Why?
| | Pharmacogenetics | 5 | 2024 | 179 | 1.170 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2025 | 383 | 1.160 |
Why?
| | Adverse Drug Reaction Reporting Systems | 4 | 2024 | 77 | 1.140 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 331 | 1.120 |
Why?
| | Electronic Health Records | 7 | 2024 | 1036 | 1.050 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 24 | 1.020 |
Why?
| | Hospitalization | 10 | 2024 | 2195 | 0.920 |
Why?
| | Propanolamines | 3 | 2019 | 96 | 0.920 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 442 | 0.890 |
Why?
| | Workflow | 1 | 2024 | 165 | 0.830 |
Why?
| | Telemedicine | 4 | 2024 | 847 | 0.810 |
Why?
| | Torsades de Pointes | 4 | 2016 | 23 | 0.760 |
Why?
| | Seasons | 1 | 2024 | 544 | 0.750 |
Why?
| | Pulmonary Edema | 1 | 2021 | 106 | 0.730 |
Why?
| | Humans | 85 | 2025 | 136783 | 0.720 |
Why?
| | Coffee | 1 | 2021 | 17 | 0.710 |
Why?
| | Stroke | 2 | 2021 | 1129 | 0.690 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 64 | 0.680 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 460 | 0.670 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 315 | 0.660 |
Why?
| | Aged | 31 | 2025 | 23729 | 0.640 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 80 | 0.620 |
Why?
| | Prosthesis Failure | 1 | 2020 | 116 | 0.620 |
Why?
| | Long QT Syndrome | 3 | 2016 | 70 | 0.610 |
Why?
| | Spironolactone | 1 | 2019 | 35 | 0.610 |
Why?
| | Mobile Applications | 1 | 2021 | 180 | 0.610 |
Why?
| | Device Removal | 1 | 2020 | 138 | 0.600 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 119 | 0.600 |
Why?
| | United States | 21 | 2024 | 14660 | 0.600 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 54 | 0.590 |
Why?
| | Medical Records | 2 | 2019 | 172 | 0.590 |
Why?
| | Coronary Disease | 1 | 2021 | 385 | 0.580 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1033 | 0.580 |
Why?
| | Biomedical Research | 2 | 2024 | 689 | 0.580 |
Why?
| | Periodicals as Topic | 1 | 2020 | 210 | 0.570 |
Why?
| | Mortality | 3 | 2019 | 357 | 0.560 |
Why?
| | Retrospective Studies | 21 | 2024 | 15564 | 0.550 |
Why?
| | Risk Assessment | 8 | 2024 | 3429 | 0.540 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 68 | 0.530 |
Why?
| | Female | 48 | 2025 | 72840 | 0.530 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 59 | 0.530 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 991 | 0.520 |
Why?
| | Hospital Records | 1 | 2016 | 12 | 0.520 |
Why?
| | Proteoglycans | 1 | 2017 | 107 | 0.510 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 390 | 0.510 |
Why?
| | Hospital Mortality | 6 | 2024 | 900 | 0.510 |
Why?
| | Ventricular Function, Left | 5 | 2025 | 540 | 0.510 |
Why?
| | Artificial Intelligence | 1 | 2019 | 272 | 0.500 |
Why?
| | Disease Management | 1 | 2020 | 623 | 0.480 |
Why?
| | Survival | 1 | 2015 | 38 | 0.480 |
Why?
| | Tetrazoles | 1 | 2015 | 40 | 0.480 |
Why?
| | Middle Aged | 29 | 2025 | 33200 | 0.480 |
Why?
| | Male | 40 | 2025 | 67361 | 0.470 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 63 | 0.470 |
Why?
| | Muscle Proteins | 2 | 2025 | 229 | 0.460 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1045 | 0.460 |
Why?
| | Research Design | 1 | 2020 | 1107 | 0.440 |
Why?
| | Ventricular Remodeling | 3 | 2025 | 262 | 0.430 |
Why?
| | Registries | 2 | 2020 | 2015 | 0.430 |
Why?
| | Loperamide | 2 | 2023 | 11 | 0.430 |
Why?
| | Myocardium | 3 | 2017 | 1002 | 0.410 |
Why?
| | Adult | 28 | 2024 | 37616 | 0.410 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 174 | 0.400 |
Why?
| | Diet | 1 | 2021 | 1273 | 0.400 |
Why?
| | Precision Medicine | 6 | 2024 | 426 | 0.400 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2190 | 0.400 |
Why?
| | Legislation, Medical | 1 | 2012 | 11 | 0.390 |
Why?
| | Amiodarone | 1 | 2012 | 26 | 0.390 |
Why?
| | Peripartum Period | 4 | 2022 | 17 | 0.390 |
Why?
| | Quality Improvement | 2 | 2020 | 1152 | 0.380 |
Why?
| | Patient Readmission | 1 | 2018 | 695 | 0.380 |
Why?
| | Phenotype | 5 | 2025 | 3199 | 0.380 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 114 | 0.370 |
Why?
| | Heart Arrest | 4 | 2019 | 339 | 0.360 |
Why?
| | Catheter Ablation | 1 | 2015 | 349 | 0.360 |
Why?
| | Sex Factors | 4 | 2024 | 2068 | 0.350 |
Why?
| | Pyrazines | 2 | 2008 | 91 | 0.350 |
Why?
| | Treatment Outcome | 10 | 2025 | 10764 | 0.350 |
Why?
| | Transfusion Reaction | 1 | 2011 | 46 | 0.340 |
Why?
| | Triazoles | 2 | 2008 | 147 | 0.340 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2108 | 0.340 |
Why?
| | Forecasting | 2 | 2024 | 384 | 0.340 |
Why?
| | Postoperative Complications | 2 | 2020 | 2624 | 0.340 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 552 | 0.330 |
Why?
| | Echocardiography | 3 | 2024 | 659 | 0.330 |
Why?
| | Patient Transfer | 1 | 2012 | 165 | 0.330 |
Why?
| | Insurance, Health | 1 | 2012 | 278 | 0.330 |
Why?
| | Patient Discharge | 2 | 2021 | 896 | 0.320 |
Why?
| | Databases, Factual | 5 | 2020 | 1347 | 0.310 |
Why?
| | Anemia | 1 | 2011 | 170 | 0.310 |
Why?
| | Risk Factors | 9 | 2024 | 10331 | 0.310 |
Why?
| | Thiazolidinediones | 1 | 2010 | 137 | 0.310 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7569 | 0.310 |
Why?
| | Marketing | 1 | 2008 | 32 | 0.300 |
Why?
| | Renal Insufficiency | 1 | 2011 | 156 | 0.300 |
Why?
| | Genotype | 3 | 2024 | 1919 | 0.300 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 22 | 0.300 |
Why?
| | Simvastatin | 1 | 2008 | 61 | 0.290 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 45 | 0.290 |
Why?
| | Heart Ventricles | 4 | 2017 | 792 | 0.290 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 46 | 0.280 |
Why?
| | Heart Rate | 3 | 2025 | 823 | 0.280 |
Why?
| | Length of Stay | 4 | 2024 | 1208 | 0.280 |
Why?
| | Electrocardiography | 4 | 2019 | 628 | 0.280 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 30 | 0.280 |
Why?
| | Drug Industry | 1 | 2008 | 108 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 891 | 0.280 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1260 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1294 | 0.270 |
Why?
| | Pharmacovigilance | 2 | 2024 | 23 | 0.260 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 180 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5115 | 0.250 |
Why?
| | Incidence | 5 | 2024 | 2788 | 0.250 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 102 | 0.250 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 2050 | 0.250 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 400 | 0.240 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2603 | 0.240 |
Why?
| | Cause of Death | 2 | 2019 | 429 | 0.230 |
Why?
| | Glucose | 1 | 2010 | 1019 | 0.230 |
Why?
| | New York | 1 | 2024 | 129 | 0.220 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2024 | 36 | 0.220 |
Why?
| | Pandemics | 3 | 2022 | 1619 | 0.220 |
Why?
| | Young Adult | 9 | 2022 | 13126 | 0.220 |
Why?
| | Pregnancy | 6 | 2022 | 6731 | 0.220 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 811 | 0.210 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1455 | 0.210 |
Why?
| | Adolescent | 10 | 2020 | 21463 | 0.210 |
Why?
| | Monitoring, Physiologic | 1 | 2024 | 267 | 0.200 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 66 | 0.200 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 831 | 0.200 |
Why?
| | Medicare | 2 | 2020 | 747 | 0.190 |
Why?
| | Prognosis | 5 | 2020 | 4018 | 0.190 |
Why?
| | Naltrexone | 1 | 2023 | 97 | 0.190 |
Why?
| | Insulin Resistance | 1 | 2010 | 1201 | 0.180 |
Why?
| | Time Factors | 3 | 2020 | 6792 | 0.180 |
Why?
| | Speech | 1 | 2021 | 73 | 0.180 |
Why?
| | Red Meat | 1 | 2021 | 18 | 0.180 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 349 | 0.180 |
Why?
| | Smartphone | 1 | 2021 | 91 | 0.180 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 23 | 0.170 |
Why?
| | Losartan | 1 | 2020 | 14 | 0.170 |
Why?
| | Lisinopril | 1 | 2020 | 13 | 0.170 |
Why?
| | Actigraphy | 1 | 2021 | 109 | 0.170 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1281 | 0.170 |
Why?
| | Protective Factors | 1 | 2021 | 93 | 0.170 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1284 | 0.170 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 46 | 0.170 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 52 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2021 | 53 | 0.170 |
Why?
| | American Heart Association | 2 | 2019 | 306 | 0.170 |
Why?
| | Referral and Consultation | 2 | 2017 | 777 | 0.170 |
Why?
| | Data Accuracy | 1 | 2020 | 63 | 0.170 |
Why?
| | Milk | 1 | 2021 | 124 | 0.170 |
Why?
| | Biological Products | 1 | 2023 | 215 | 0.160 |
Why?
| | California | 2 | 2012 | 424 | 0.160 |
Why?
| | Indans | 1 | 2020 | 11 | 0.160 |
Why?
| | Oxadiazoles | 1 | 2020 | 33 | 0.160 |
Why?
| | Bionics | 1 | 2019 | 12 | 0.160 |
Why?
| | Editorial Policies | 1 | 2020 | 51 | 0.160 |
Why?
| | Medical Futility | 1 | 2019 | 23 | 0.160 |
Why?
| | Medical Informatics | 1 | 2020 | 100 | 0.160 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.160 |
Why?
| | Software | 2 | 2015 | 663 | 0.160 |
Why?
| | Medical Record Linkage | 1 | 2020 | 64 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2020 | 109 | 0.160 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 117 | 0.160 |
Why?
| | Drug Overdose | 1 | 2023 | 344 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 76 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2021 | 247 | 0.150 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 33 | 0.150 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 43 | 0.150 |
Why?
| | Social Determinants of Health | 1 | 2022 | 250 | 0.150 |
Why?
| | Child Health Services | 1 | 2020 | 185 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2045 | 0.150 |
Why?
| | Tobacco Use | 1 | 2019 | 65 | 0.150 |
Why?
| | Cohort Studies | 3 | 2021 | 5718 | 0.150 |
Why?
| | Computer Graphics | 2 | 2015 | 41 | 0.150 |
Why?
| | Cluster Analysis | 1 | 2019 | 495 | 0.140 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 308 | 0.140 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 8 | 0.140 |
Why?
| | Florida | 1 | 2018 | 101 | 0.140 |
Why?
| | Advisory Committees | 1 | 2019 | 219 | 0.140 |
Why?
| | Porins | 1 | 1997 | 14 | 0.140 |
Why?
| | Neisseria gonorrhoeae | 1 | 1997 | 25 | 0.140 |
Why?
| | Dyslipidemias | 1 | 2019 | 176 | 0.130 |
Why?
| | Prospective Studies | 4 | 2021 | 7583 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 497 | 0.130 |
Why?
| | Nursing Assessment | 1 | 2017 | 55 | 0.130 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 488 | 0.130 |
Why?
| | Pressure Ulcer | 1 | 2017 | 35 | 0.130 |
Why?
| | Patient Participation | 1 | 2020 | 416 | 0.130 |
Why?
| | Population Surveillance | 1 | 2020 | 470 | 0.130 |
Why?
| | Heart Diseases | 1 | 2020 | 359 | 0.130 |
Why?
| | Cardiology | 1 | 2019 | 278 | 0.130 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 116 | 0.130 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 679 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2025 | 1981 | 0.120 |
Why?
| | Genetic Markers | 1 | 2017 | 344 | 0.120 |
Why?
| | Oxycodone | 1 | 2016 | 44 | 0.120 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 5 | 0.120 |
Why?
| | Databases, Genetic | 1 | 2017 | 236 | 0.120 |
Why?
| | Rheumatic Fever | 1 | 2015 | 9 | 0.120 |
Why?
| | Sex Distribution | 1 | 2016 | 376 | 0.120 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 20 | 0.120 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 38 | 0.120 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 22 | 0.120 |
Why?
| | Angiotensin II | 1 | 2015 | 99 | 0.120 |
Why?
| | Naloxone | 1 | 2016 | 120 | 0.120 |
Why?
| | Computational Biology | 2 | 2017 | 645 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1768 | 0.110 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 44 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 203 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 890 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 765 | 0.110 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 478 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 752 | 0.110 |
Why?
| | United Kingdom | 1 | 2015 | 315 | 0.110 |
Why?
| | International Classification of Diseases | 1 | 2015 | 131 | 0.110 |
Why?
| | Biomarkers | 2 | 2024 | 4158 | 0.110 |
Why?
| | Comorbidity | 1 | 2019 | 1611 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 3290 | 0.110 |
Why?
| | Chronic Disease | 2 | 2020 | 1784 | 0.110 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 178 | 0.100 |
Why?
| | Gene Expression | 2 | 2017 | 1499 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 389 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 657 | 0.100 |
Why?
| | Cholesterol | 1 | 2015 | 410 | 0.100 |
Why?
| | MicroRNAs | 2 | 2017 | 697 | 0.100 |
Why?
| | Federal Government | 1 | 2012 | 27 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 702 | 0.100 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 528 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2017 | 2831 | 0.100 |
Why?
| | Drug Resistance | 1 | 2012 | 169 | 0.100 |
Why?
| | Area Under Curve | 1 | 2012 | 313 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 304 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2417 | 0.090 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 147 | 0.090 |
Why?
| | Colorado | 4 | 2024 | 4491 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2030 | 0.090 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 132 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 232 | 0.090 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 409 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1042 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2012 | 400 | 0.090 |
Why?
| | Survival Rate | 1 | 2015 | 1969 | 0.090 |
Why?
| | Managed Care Programs | 2 | 2022 | 129 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 227 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1434 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 939 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 548 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1513 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2831 | 0.080 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 35 | 0.070 |
Why?
| | Primary Health Care | 1 | 2019 | 1714 | 0.070 |
Why?
| | Drug Approval | 1 | 2008 | 87 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2010 | 331 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2060 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 159 | 0.070 |
Why?
| | Animals | 3 | 2023 | 36768 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 251 | 0.060 |
Why?
| | Zimbabwe | 2 | 2017 | 55 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 504 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1059 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1769 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 35 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3537 | 0.060 |
Why?
| | Depression | 2 | 2022 | 1402 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 138 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 41 | 0.060 |
Why?
| | Potassium Channels | 1 | 2025 | 150 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5417 | 0.050 |
Why?
| | Mandible | 1 | 2004 | 78 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 33 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 783 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 160 | 0.050 |
Why?
| | Algorithms | 3 | 2020 | 1686 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 39 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 83 | 0.050 |
Why?
| | Child | 5 | 2020 | 21968 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 3 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 129 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 181 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 12 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 34 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 24 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2022 | 235 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2020 | 150 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 322 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 320 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 500 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 34 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2129 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 40 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 522 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 209 | 0.040 |
Why?
| | Bias | 1 | 2020 | 218 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2812 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 790 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2162 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 312 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 256 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2145 | 0.030 |
Why?
| | Static Electricity | 1 | 1997 | 120 | 0.030 |
Why?
| | Exercise Test | 1 | 2020 | 625 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2903 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 81 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 499 | 0.030 |
Why?
| | Focus Groups | 1 | 2019 | 508 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 129 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1281 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 343 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 32 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 182 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 544 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 122 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2644 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 344 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 94 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 115 | 0.030 |
Why?
| | Cell Membrane | 1 | 1997 | 736 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1772 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1126 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3272 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1112 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 605 | 0.020 |
Why?
| | Mass Screening | 2 | 2013 | 1262 | 0.020 |
Why?
| | Infant | 2 | 2015 | 9442 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1938 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 48 | 0.020 |
Why?
| | Child, Preschool | 2 | 2015 | 11069 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 101 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 92 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 5065 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1043 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 201 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 886 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2548 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 205 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 101 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 751 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 408 | 0.020 |
Why?
| | Mice | 1 | 2023 | 17731 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 498 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 804 | 0.010 |
Why?
| | Hospitals, University | 1 | 2005 | 180 | 0.010 |
Why?
| | Dentists | 1 | 2004 | 20 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 63 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 62 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1428 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 253 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 173 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 26 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1318 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 487 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 636 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1308 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 1093 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 897 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|